Canadian Urological Association journal = Journal de l’Association des urologues du Canada 2017 11 11() doi 10.5489/cuaj.4473
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) type-III is a common disorder characterized by pelvic pain and lower urinary tract symptoms in the absence of active infection. The aim of this clinical study is to evaluate the results of thermobalancing therapy (TT) and to discus the possible etiology and pathophysiology of CP/CPPS.
45 patients with CP/CPPS used TT by applying therapeutic device, namely Dr Allen’s therapeutic device (DATD), for six months as monotherapy. The control group comprised 45 men who did not receive TT. The National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores, prostatic volume (PV) by ultrasound measurement, and uroflowmetry (Qmax) were compared between both groups.
Compared to controls, the treatment group showed significant improvements from baseline to endpoint in pain score, (p<0.001), quality of life index (QoL) (p<0.001), PV (p<0.001), and Qmax (p<0.001). CONCLUSIONS
The clinical study has confirmed that six-month TT with DATD reduces CP/CPPS symptoms dramatically. DATD uses emitted body heat as a source of energy to the projection of prostate for a pronged period of time, which removes microfocus of hypothermia in the prostate tissue gradually, improving blood circulation and consequently relieving the problem. Thus, the etiology and pathophysiology of CP/CPPS may be viewed as a chain of events in which initial inflammation in the prostate tissue leads to spontaneous capillary expansion, increasing pressure in the gland that sets up secondary, continuous-trigger, microfocus of hypothermia. It makes the problem chronic. TT, by eliminating this focus of hypothermia and pressure in the prostate gland, provides pelvic pain relief and improves QoL of men with CP/CPPS. The effectiveness of therapy allows us to recommend DATD for patients with CP/CPPS.